| 摘要: |
| 目的 分析注射用拉氧头孢的药品不良反应(adverse drug reaction, ADR)报告数据,为临床合理用药提供依据。方法 采用回顾性分析研究的方法,对2019年1月至2023 年12月期间,山东省药品不良反应监测中心数据库中收集到的经药品关联性评价评定为肯定、很可能以及可能的注射用拉氧头孢ADR报告,并对报告中注射用拉氧头孢所致的ADR报告中的患者年龄及性别、不良反应报告情况及ADR因果关系、原发疾病、用法用量、ADR累及器官-系统分布、ADR的发生时间、新的和严重的不良反应以及转归情况等进行统计分析。结果 共收集到426例注射用拉氧头孢所致的ADR报告,其中0~10岁分布最多,共219例次(51.41%);原患疾病以呼吸系统损害为主,共126例次(29.58%);注射用拉氧头孢的给药途径以静脉滴注给药为主,共417例次(97.89%);ADR的发生时间主要集中在用药1 h以内(67.37%);ADR累及器官-系统共涉及12项,以皮肤及附件损害最多,共456例次(71.59%);在426例ADR报告中有271例患者痊愈,154例患者好转,1例患者转归不详。结论 临床应加强对注射用拉氧头孢的用药管理,严格遵照说明书用药并加强对用药患者的监护,能够有效的减少不良反应的发生。 |
| 关键词: 注射用拉氧头孢 药品不良反应 统计分析 病例报告 合理用药 药物警戒 |
| DOI:10.13506/j.cnki.jpr.2025.11.015 |
| 基金项目:山东中医药学会临床药学科研专项基金项目(No.SDACM202204);山东省医药卫生科技项目(No.202313010888) |
|
出版日期:2025-11-25
|
|
| Analysis of 426 cases of adverse reaction reports of Latamoxef for Injection |
| SUN Yushen1,LI Wei1,HAN Congxiao2,LIU Qun2,LIU Xiaoqian2,LU Changfei3 |
| (1. Shandong University of Traditional Chinese Medicine, Jinan 250355, China; 2. Department of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China; 3. Shandong Adverse Drug Reaction Monitoring Center, Jinan 250013, China) |
| Abstract: |
| Objective To analyze the adverse drug reaction( ADR )report data of latamoxef for injection, and to provide the basis for clinical rational drug use.Methods Using the method of retrospective analysis and research, the ADR reports of latamoxef for injection collected in the database of Shandong Provincial Adverse Drug Reaction Monitoring Center from January 2019 to December 2023 were evaluated as positive, probable and possible by drug relevance evaluation. The age and gender of the patients in the ADR report caused by latamoxef for injection, the report of adverse reactions and the causality of ADR, the primary disease, usage and dosage, the distribution of ADR-involved organs and systems, the occurrence time of ADR,the new and serious adverse reactions and prognosis of ADR were statistically analyzed.Results 426 cases of ADR caused by latamoxef for injection were most distributed in children aged 0-10 years old, with a total of 219( 51.41% ) cases. The primary disease was mainly respiratory infection, with a total of 126 ( 29.58% )cases. The main route of administration of latamoxef for injection was intravenous drip, with a total of 417 ( 97.89% ) cases. The occurrence time of ADR was mainly within 1 h( 67.37% ). There were 12 organs and systems involved in ADR, with the most damage to skin and accessories, a total of 456 ( 71.59% ) cases. Among the 426 ADR reports, 271 patients were cured, 154 patients were improved, and 1 patient 's outcome was unknown.Conclusion The clinical management of latamoxef for injection should be strengthened, strictly follow the instructions and strengthen the monitoring of patients, which can effectively reduce the occurrence of adverse reactions. |
| Key words: Latoxefin for injection Adverse drug reaction Statistical analysis Case report Rational administration of drugs Pharmacovigilance |